Residential College | false |
Status | 已發表Published |
In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy | |
Weijing Yang1,3; Guizhi Zhu3; Sheng Wang3; Guocan Yu3; Zhen Yang3; Lisen Lin3; Zijian Zhou3; Yijing Liu3; Yunlu Dai3; Fuwu Zhang3; Zheyu Shen3; Yuan Liu3; Zhimei He3; Joseph Lau3; Gang Niu3; Dale O. Kiesewetter3; Shuo Hu1,2; Xiaoyuan Chen3 | |
2019-03-05 | |
Source Publication | ACS NANO |
ISSN | 1936-0851 |
Volume | 13Issue:3Pages:3083-3094 |
Abstract | A cancer vaccine is an important form of immunotherapy. Given their effectiveness for antigen processing and presentation, dendritic cells (DCs) have been exploited in the development of a therapeutic vaccine. Herein, a versatile polymersomal nanoformulation that enables generation of tumor-associated antigens (TAAs) and simultaneously serves as adjuvant for an in situ DC vaccine is reported. The chimeric cross-linked polymersome (CCPS) is acquired from self-assembly of a triblock copolymer, polyethylene glycol-poly(methyl methyacrylateco-2-amino ethyl methacrylate (thiol/amine))-poly 2- (dimethylamino)ethyl methacrylate (PEG-P(MMA-coAEMA (SH/NH2)-PDMA). CCPS can encapsulate lowdose doxorubicin hydrochloride (DOX) to induce immunogenic cell death (ICD) and 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH), a photosensitizer to facilitate photodynamic therapy (PDT) for reactive oxygen species (ROS) generation. This combination is able to enhance the population of TAAs and DC recruitment, eliciting an immune response cascade. In addition, CCPS with primary and tertiary amines act as adjuvant, both of which can stimulate DCs recruited to form an in situ DC vaccine after combination with TAAs for MC38 colorectal cancer treatment. In vivo results indicate that the all-in-one polymersomal nanoformulation (CCPS/HPPH/DOX) increases mature DCs in tumordraining lymph nodes (tdLNs) and CD8+ T cells in tumor tissues to inhibit primary and distant MC38 tumor growth following a single intravenous injection with a low dose of DOX and HPPH. |
Keyword | Immunogenetic Cell Death Photodynamic Therapy Polymersomes As Adjuvant In Situ Dc vaccIne Colorectal Cancer Immunotherapy |
DOI | 10.1021/acsnano.8b08346 |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Chemistry ; Science & Technology - Other Topics ; Materials Science |
WOS Subject | Chemistry, Multidisciplinary ; Chemistry, Physical ; Nanoscience & Nanotechnology ; Materials Science, Multidisciplinary |
WOS ID | WOS:000462950500036 |
Publisher | AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA |
Scopus ID | 2-s2.0-85062860675 |
Fulltext Access | |
FWCI | 10.976744 |
Citation statistics | |
Document Type | Journal article |
Collection | Personal research not belonging to the institution |
Corresponding Author | Shuo Hu; Xiaoyuan Chen |
Affiliation | 1.Department of PET Center, Xiangya Hospital, Central South University, Changsha, 410008, China 2.National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University, Changsha, 410008, China 3.Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland 20892, United States |
Recommended Citation GB/T 7714 | Weijing Yang,Guizhi Zhu,Sheng Wang,et al. In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy[J]. ACS NANO,2019,13(3):3083-3094. |
APA | Weijing Yang,Guizhi Zhu,Sheng Wang,Guocan Yu,Zhen Yang,Lisen Lin,Zijian Zhou,Yijing Liu,Yunlu Dai,Fuwu Zhang,Zheyu Shen,Yuan Liu,Zhimei He,Joseph Lau,Gang Niu,Dale O. Kiesewetter,Shuo Hu,&Xiaoyuan Chen.(2019).In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy.ACS NANO,13(3),3083-3094. |
MLA | Weijing Yang,et al."In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy".ACS NANO 13.3(2019):3083-3094. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment